NC-XILIS-INC
Xilis, Inc., a pioneering biotechnology company developing its MicroOrganoSphere™ (MOS™) technology to guide precision therapy for cancer patients and accelerate drug discovery and development, has closed an extension of over US$19 million to its Series A financing round, bringing the total amount raised to over US$89 million. New investor FPV Ventures led the extension, with participation from fellow new investor Alexandria Venture Investments and existing investors EQT Life Sciences, Mubadala Capital Management, Pear Ventures, GV (formerly Google Ventures), the Duke Angel Network, Catalio Capital Management, Two Sigma Ventures, Felicis Ventures, Alix Ventures and other strategic partners.
“Despite unprecedented market conditions in the biotech sector, we raised this extension at a step-up valuation and from several of the most reputable global investors. Our investors are strongly encouraged by the progress we have made in building diagnostic programs that predict patient response and achieving significant traction in partnered drug discovery and development,” said Xiling Shen, PhD, Founder and Chief Executive Officer of Xilis. “Our MOS technology is the first end-to-end, high-throughput patient-derived model drug discovery platform to identify drug candidates with a high probability of clinical success.”
The company will use the Series A funding to advance its proprietary MOS platform. This innovative MOS technology is the first truly scalable patient-derived model that recapitulates the tumor microenvironment and immune interactions necessary for next-generation immuno-oncology and cell therapy drug discovery. In addition, the MOS platform can be applied in a clinical setting to aid clinicians to make precision oncology treatment decisions, identifying treatments that lead to the best response for each patient.
“Xilis has pushed forward and achieved meaningful scientific breakthroughs that will change the way cancer drugs are being discovered and how patients are being selected to achieve the most optimal response – realizing the goal of personalized precision oncology,” said Wesley Chan, Co-Founder & Managing Partner of FPV Ventures. “With support from a world-class investor consortium, Xilis is set to continue its efforts in clinical diagnostics and accelerate the company’s growth by expanding its MOS technology into biopharma R&D and drug development.”
Recently, the company announced its participation in the Netherlands-based Oncode-PACT Consortium to accelerate the development of cancer drugs and was selected as the cover article/story in the June issue of the journal Cell Stem Cell highlighting its MOS technology and application in precision oncology.
"Xilis' innovative MOS technology can enable unlocking the full potential of patient-derived microtumors by accelerating their use both in the clinic and for drug discovery and development," said John de Koning, Partner at EQT Life Sciences. "Patients will benefit greatly from Xilis’ precision oncology treatment decisions by avoiding time spent on treatment cycles that are ineffective, and instead, receive therapies with the greatest potential of success quickly and efficiently."
About Xilis
Based in Durham, North Carolina, Xilis, Inc. is a biotechnology company developing a precision oncology platform that guides treatment decisions for oncologists to improve cancer care outcomes for patients and enables drug discovery and development with pharmaceutical companies. Xilis’ proprietary MicroOrganoSphere™ (MOS) technology consists of miniature patient tumors that capture the full microenvironment and heterogeneity and provides an automated and scalable solution. Using MOS and AI-driven algorithms, Xilis is developing a Xilis Response Score™ for the clinic, enabling oncologists to make informed and timely treatment decisions. Additionally, the MOS technology is speeding up the discovery and clinical development of new drug candidates.
To learn more about Xilis, visit our website at Xilis.com or follow us on LinkedIn .
About FPV
FPV is a new $450m fund focused on backing and serving mission-driven founders throughout their entire journey. Founded by Wesley Chan (Founder of Google Analytics and Google Voice) and Pegah Ebrahimi (former COO of Morgan Stanley Tech Banking and COO of Cisco Collaboration), the firm has backed well-known, high-impact startups including Canva, Flexport, Guild Education, Xilis, and Manifold Bio.
About EQT Life Sciences
EQT Life Sciences was formed in 2022 following an integration of LSP, a leading European life sciences venture capital firm, into the EQT platform. As LSP, the firm raised over EUR 3.0 billion (USD 3.5 billion) and supported the growth of more than 150 companies since it started to invest over 30 years ago. With a dedicated team of highly experienced investment professionals, coming from backgrounds in medicine, science, business, and finance, EQT Life Sciences backs the smartest inventors who have ideas that could truly make a difference for patients.
The team combines deep sector knowledge, analytical skills, and investment experience to provide the added value that inventors seek. EQT Life Sciences’ broad life sciences and healthcare network is highly complementary to EQT’s global healthcare sector franchise and makes EQT an even better and more innovative healthcare investor. More info: www.eqtgroup.com/lifesciences
View source version on businesswire.com: https://www.businesswire.com/news/home/20220713005121/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Xsolla Expands Payment Coverage in Portugal With MB Way, a Leading Mobile Wallet Trusted by 6 Million Customers, to Unlock New Growth Opportunities for Game Developers20.1.2026 16:41:00 CET | Press release
Empowering Portuguese players with Seamless, Localized Payment Options for a Smoother and More Trusted Gaming Experience Xsolla, a global video game commerce company that helps developers launch, grow, and monetize their games, today announced the expansion of its payments solution in Portugal with the addition of MB Way. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260120938007/en/ Graphic: Xsolla Portugal is a leader in digital transformation, with nearly 90% of its population online, high smartphone usage, and a strong adoption of mobile banking. Trusted by 6 million people, connected to 11 million cards, supported by 28 banks, and driving 496 million transactions in 2024, MB Way provides 95% market coverage, allowing most bank customers to use the service. MB Way is the leading mobile wallet in Portugal, with an estimated market share of 34%-45% of all e-commerce transactions locally. By adding MB Way as a payment meth
Balena Secures Strategic Growth Investment to Accelerate Edge AI and IoT Fleet Management20.1.2026 15:14:00 CET | Press release
New partnership fuels product innovation and reinforces Balena’s position as the leading hardware-agnostic platform dedicated to the security and long-term stability of device fleets Balena, the leading platform for deploying, managing, and scaling fleets of edge computing and AI devices, today announced a strategic growth investment from LoneTree Capital (“LoneTree”), a New York-based growth capital firm. The partnership will accelerate Balena’s product innovation with a focus on Edge AI workloads and security features to meet evolving compliance needs, while expanding resources for customer success and global fleet support. Founded in 2011, Balena enables customers to leverage the ever-increasing power of technology to solve real-world problems by providing software to manage the full lifecycle of edge computing devices. The platform abstracts away infrastructure complexity, handling critical tasks like secure Over-The-Air (OTA) updates so engineering teams can focus on their core pr
SIRBAI Launches Middle East’s First AI-Powered Autonomous Drone Swarm Technology at UMEX 202620.1.2026 15:11:00 CET | Press release
New platform enables coordinated, autonomous drone operations designed for modern defense environments SIRBAI today announced the official launch of the Middle East’s first AI-powered autonomous drone swarm technology at UMEX 2026 - a global exhibition platform for unmanned systems and autonomous capabilities - marking the company’s entry into the defense technology sector. Designed for unmanned aerial systems (UAS), the platform enables multiple drones to operate collaboratively with a high degree of autonomy, even in complex and contested environments. As the first company in the region to offer this advanced capability, SIRBAI is set to redefine the modern battlefield with innovative and scalable autonomous technology, establishing new standards for resilient and operator-friendly mission systems for modern defense operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260120186459/en/ SIRBAI Launches Middle East’s Fi
FlightSafety International Receives EASA and UK CAA Certification for Gulfstream G700 Flight Simulator at Farnborough Learning Centre20.1.2026 15:05:00 CET | Press release
Certification advances training support and builds on FlightSafety’s decades-long partnership with Gulfstream Aerospace Corp. FlightSafety International Inc. (FSI), a global leader in aviation training and simulation technology, announced today it has received European Union Aviation Safety Agency (EASA) and UK Civil Aviation Authority (CAA) certification for its Gulfstream G700 Full Flight Simulator (FFS), located at the company’s Farnborough Learning Centre. The certification of the simulator, which was engineered and manufactured by FSI, validates the advanced technology, accuracy, and fidelity of the flight training device, confirming it meets the highest European and UK regulatory standards. The FFS will be leveraged for initial, recurrent, and advanced pilot training to support G700 and Gulfstream G800 aircraft, further expanding global access to high-fidelity training. “The G700 simulator certification in Farnborough reinforces FSI’s long-standing commitment to supporting Gulfst
OPEX® and Peltier Partner to Deliver First-of-Its-Kind Cold Storage Solution for Automated Fulfillment Systems20.1.2026 15:00:00 CET | Press release
OPEX® Corporation, a global leader in Next Generation Automation providing innovative solutions for warehouse, document and mail automation, today announced a strategic technology partnership with Peltier, an innovator in cold chain commerce, to offer a first-of-its-kind, multi-temperature zone, multi-deep cold storage solution for automated fulfillment systems. This collaboration introduces advanced multi-temperature capabilities to OPEX Corporation’s industry-leading Perfect Pick® and Infinity® automated storage and retrieval systems (ASRS), empowering customers in the grocery, pharmaceutical, and life sciences markets to seamlessly store and retrieve chilled and frozen products utilizing Peltier’s actively cooled, AI-enabled totes, eliminating the need for costly freezer chambers or specialized infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260120776429/en/ OPEX iBOTs efficiently transport and present Pelt
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom